AbCellera Biologics Inc. (ABCL)
| Market Cap | 3.72B +213.3% |
| Revenue (ttm) | 67.85M +92.1% |
| Net Income | -148.30M |
| EPS | -0.48 |
| Shares Out | 324.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,677,637 |
| Open | 11.75 |
| Previous Close | 11.62 |
| Day's Range | 11.06 - 11.83 |
| 52-Week Range | 2.75 - 15.02 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+56.66%) |
| Earnings Date | Nov 9, 2026 |
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil... [Read more]
Financial Performance
In 2025, AbCellera Biologics's revenue was $75.13 million, an increase of 160.56% compared to the previous year's $28.83 million. Losses were -$146.41 million, -10.10% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 56.66% from the latest price.
News
AbCellera price target raised to $15 from $11 at StoneX
StoneX raised the firm’s price target on AbCellera (ABCL) to $15 from $11 and keeps a Buy rating on the shares.
AbCellera Biologics Transcript: Stifel 2026 Healthcare Conference 2026
ABCL635 showed substantially greater hot-flash reduction than approved small molecules in phase II, with a clean safety profile and potential monthly dosing. Late-stage VMS development and oncology studies are planned for next year.
AbCellera reports Q3 EPS (19c), consensus (18c)
Reports Q3 revenue $10.6M, consensus $6.3M. “This was a transformative quarter for AbCellera (ABCL), highlighted by strong clinical execution and balance sheet expansion. Positive top-line Phase 2 res...
AbCellera price target raised to $14 from $9 at Stifel
Stifel raised the firm’s price target on AbCellera (ABCL) to $14 from $9 and keeps a Buy rating on the shares.
AbCellera Biologics Earnings Call Transcript: Q3 2026
ABCL635’s phase II results support planned 2027 late-stage development, while new programs broaden the pipeline. A $200 million raise and over $890 million in available liquidity support investment; Q3 net loss narrowed YoY.
AbCellera Biologics Slides: Q3 2026
AbCellera Biologics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 9, 2026.
AbCellera Biologics Earnings release: Q3 2026
AbCellera Biologics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
AbCellera Biologics Quarterly report: Q3 2026
AbCellera Biologics has published its Q3 2026 quarterly earnings report on November 9, 2026.
AbCellera Reports Q3 2026 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business Results.
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026.
AbCellera initiated with a Buy at Jefferies
Jefferies analyst Roger Song initiated coverage of AbCellera (ABCL) with a Buy rating and $21 price target ABCL635 is the first clinical proof that AbCellera is turning a proven antibody…
AbCellera to Present at Upcoming Investor Conferences in November 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November 2026.
AbCellera initiated with a Buy at UBS
UBS initiated coverage of AbCellera (ABCL) with a Buy rating and $18 price target The firm believes ABCL635 is a “potentially transformative therapy” in menopausal hot flashes, with a $13B…
AbCellera to present Phase 1/2 data for ABCL635 at TMS 2026 Annual Meeting
AbCellera (ABCL) “announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s 2026 Annual Meeting, to be held October 20 to 24 at the Hilton…
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
AbCellera initiated with an Overweight at JPMorgan
JPMorgan analyst Brian Cheng initiated coverage of AbCellera (ABCL) with an Overweight rating and $17 price target The firm believes the stock “stands at a major value inflection point” following…
AbCellera resumed with a Neutral at Goldman Sachs
Goldman Sachs resumed coverage of AbCellera (ABCL) with a Neutral rating and $13 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite...
AbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause
AbCellera (ABCL) “announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society 20th World Congress on Menopause, to be held September 30 to October…
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
AbCellera Biologics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
ABCL635, a novel NK3R antibody, demonstrated superior efficacy and safety in phase II for VMS, with rapid progress toward phase III and strong commercial potential. The company is expanding its pipeline and leveraging its antibody platform for future growth.
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.